18
Participants
Start Date
April 22, 2022
Primary Completion Date
May 2, 2023
Study Completion Date
November 30, 2025
ARO-ANG 3 Injection
Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period
Research Site 8, Camperdown
Research Site 7, Johannesburg
Research Site 3, Nedlands
Research Site 4, Mount Sinai
Research Site 5, Cincinnati
Research Site 2, Chicoutimi
Research Site 1, Québec
Lead Sponsor
Arrowhead Pharmaceuticals
INDUSTRY